Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
Q3 2021 vs. Q2 2021
How the institutions holding Gain Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 14 | 14 | 0 |
| Shares | 894.3K | 892.6K | −1.67K (−0.2%) |
| Value | $8.95M | $6.65M | −$2.30M (−25.7%) |
New holders (2)
Institutions that held Gain Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Indie Asset Partners, LLC | 29,652 | $221.0K | 0.18% |
| Veritable, L.P. | 25,064 | $187.0K | 0.00% |
Sold out (2)
Institutions that held Gain Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Granite Point Capital Management, L.P. | 155,709 | $1.56M |
| Millennium Management LLC | 23,878 | $239.0K |